Inhibikase Therapeutics (IKT) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Inhibikase Therapeutics (IKT) has outperformed Ocugen (OCGN) over the past year, gaining 18.7% versus a loss of 47.8%. Over five years, IKT leads with a -83.0% price change compared with -89.0% for OCGN. Ocugen is the larger company by market cap ($324.0 million vs $274.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | OCGN |
|---|---|---|
| Share price | $1.97 | $0.9555 |
| Market cap | $274.89M | $324.02M |
| 1-day change | +3.14% | -2.24% |
| YTD return | -3.90% | -29.22% |
| 1-year return | +18.67% | -47.79% |
| 5-year return | -82.99% | -88.97% |
| EPS (TTM) | $-0.43 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $2.73 |
| 52-week low | $1.33 | $0.90 |
| Distance from 52-week high | -24.52% | -64.94% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +204.57% | +1173.68% |
| Average volume | 650.50K | 6.06M |
| Shares outstanding | 139.54M | 339.11M |
| Employees | 35 | 116 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IKT has outperformed OCGN by 66.5 percentage points over the past year.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
IKT vs OCGN FAQ
Which is bigger, Inhibikase Therapeutics or Ocugen?
Ocugen (OCGN) is larger, with a market capitalization of $324.02M compared with $274.89M for Inhibikase Therapeutics (IKT).
Which stock has performed better over the past year, IKT or OCGN?
IKT returned +18.67% over the past 12 months, compared with -47.79% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and Ocugen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.